A 28-year-old woman from Delhi presents with a 3-month history of intermittent wheezing, chest tightness, and nocturnal cough 2–3 times per week. She denies any acute exacerbations. On examination, her peak expiratory flow (PEF) is 380 L/min (predicted 460 L/min). Spirometry shows FEV₁ 78% predicted with FEV₁/FVC ratio of 0.68. She is currently on salbutamol as needed. What is the most appropriate next step in her management?

Explanation

## Clinical Assessment This patient meets the criteria for **persistent mild asthma** (symptoms 2–3 times per week, nocturnal symptoms, and objective evidence of airflow limitation on spirometry with FEV₁ 78% predicted). ### Key Point: **Any patient with persistent asthma (symptoms more than twice per week) requires regular controller therapy, not just reliever therapy.** ## Stepwise Asthma Management Algorithm ```mermaid flowchart TD A[Asthma diagnosis confirmed]:::outcome --> B{Symptom frequency?}:::decision B -->|Intermittent: ≤2 days/week| C[SABA as needed only]:::action B -->|Persistent: >2 days/week| D[Add regular controller]:::action D --> E{Severity of persistent asthma?}:::decision E -->|Mild persistent| F[Low-dose ICS monotherapy]:::action E -->|Moderate persistent| G[Medium-dose ICS or ICS+LABA]:::action E -->|Severe persistent| H[High-dose ICS+LABA ± LTRA]:::action F --> I[Review response in 2–4 weeks]:::outcome ``` **High-Yield:** - **Mild persistent asthma** = symptoms >2 days/week but <1 day/month, or nocturnal symptoms 1–2 times/month - **First-line controller:** Low-dose ICS (e.g. beclomethasone 200 µg/day or fluticasone 100–200 µg/day) - ICS is the most effective anti-inflammatory agent and is the gold standard for all persistent asthma ## Why This Patient Needs ICS | Feature | Finding | Implication | |---------|---------|-------------| | Symptom frequency | 2–3 times/week | Persistent (not intermittent) | | Nocturnal symptoms | Present | Indicates airway inflammation | | FEV₁ | 78% predicted | Mild airflow limitation | | Current therapy | SABA only | Inadequate control | | Recommendation | Low-dose ICS | Step 2 of GINA/NAEPP guidelines | **Clinical Pearl:** ICS should be initiated promptly in persistent asthma because: 1. They reduce airway inflammation and remodeling 2. They prevent exacerbations and emergency visits 3. Early initiation improves long-term outcomes and prevents progression to moderate/severe asthma 4. They are safe at low doses with minimal systemic side effects ## Why Not Other Options? - **LABA monotherapy (option 3):** Contraindicated without concurrent ICS; LABAs increase mortality when used alone and should always be paired with ICS - **Oral corticosteroids (option 4):** Reserved for acute exacerbations or severe refractory asthma; not indicated for maintenance in mild persistent asthma - **Continued SABA monotherapy (option 1):** Inadequate for persistent asthma; reliever-only therapy is only appropriate for intermittent asthma (≤2 days/week) **Mnemonic:** **GINA Step Ladder for Persistent Asthma** — **ICS First** - Step 2 (Mild persistent): **ICS monotherapy** ← This patient is here - Step 3 (Moderate persistent): ICS + LABA or medium-dose ICS - Step 4 (Severe persistent): High-dose ICS + LABA ± LTRA - Step 5: Add biologic agents (omalizumab, mepolizumab, etc.) [cite:Harrison 21e Ch 242]